Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2016

Schedule of basic and diluted net income (loss) per share

The following table sets forth the computation of basic and diluted net loss per share:

	Three months ended March 31,
	2016		2015
Numerator:
Net loss applicable to common stockholders, basic and diluted	$	(6,775)	$	(4,115)

Denominator
Weighted-average number of shares, basic and diluted		107,718		101,791


Net loss per share, basic and diluted	$	(0.06)	$	(0.04)

Schedule of Antidilutive Securities

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	March 31,
	2016		2015
Options to purchase common stock		1,979		1,496
Warrants for common stock		4,085		1,966
Common stock issuable upon conversion of preferred shares		1,309		-
Total common stock equivalents		7,373		3,462